This study addresses common bottlenecks in the global biopharmaceutical industry, including slow R&D cycles, high compliance costs, and challenges in international market access. It proposes an evidence-based accelerated model for nutritional supplements that integrates digital intelligence, biotech innovation, and regulatory science. Centered on Australia's TGA pharmaceutical-grade regulatory framework, the model establishes an integrated global system encompassing R&D, efficacy validation, and international compliance. Leveraging a big data platform for active ingredients and an AI-driven formulation engine, it combines biological mechanism analysis with real-world evidence (RWE) validation. The architecture features standardized core modules and region-specific customization to accommodate global regulatory variations. A practical case study of WALVE Biotech's Revefore® ternary synergistic formulation demonstrates the model's effectiveness. Research confirms that this approach not only enhances profit margins per product unit but also enables rapid adaptation to global markets through dynamic integration with regional regulatory databases like FDA and EFSA. The model provides a high-standard, efficient R&D solution for the evidence-based nutrition industry, offering broad applicability across the sector.